医学
开胸手术
肺癌
纵隔镜检查
放射科
外科
正电子发射断层摄影术
内科学
作者
Harm van Tinteren,Otto S. Hoekstra,Egbert F. Smit,Jan HAM van den Bergh,Ad J.M. Schreurs,Roland A. L. M. Stallaert,Piet CM van Velthoven,Emile F.I. Comans,Fred W. Diepenhorst,Paul Verboom,Johan C van Mourlk,Pieter E. Postmus,Maarten Boers,Gerrit JJ Teule
出处
期刊:The Lancet
[Elsevier BV]
日期:2002-04-01
卷期号:359 (9315): 1388-1392
被引量:862
标识
DOI:10.1016/s0140-6736(02)08352-6
摘要
Summary Background Up to 50% of curative surgery for suspected non-small-cell lung cancer is unsuccessful. Accuracy of positron emission tomography (PET) with 18-fluorodeoxyglucose ( 18 FDG) is thought to be better than conventional staging for diagnosis of this malignancy. Up to now however, there has been no evidence that PET leads to improved management of patients in routine clinical practice. We did a randomised controlled trial in patients with suspected non-small-cell lung cancer, who were scheduled for surgery after conventional workup, to test whether PET with 18 FDG reduces number of futile thoracotomies. Methods Before surgery (mediastinoscopy or thoracotomy), 188 patients from nine hospitals were randomly assigned to either conventional workup (CWU) or conventional workup and PET (CWU+PET). Patients were followed up for 1 year. Thoracotomy was regarded as futile if the patient had benign disease, explorative thoracotomy, pathological stage IIIA–N2/IIIB, or postoperative relapse or death within 12 months of randomisation. The primary outcome measure was futile thoracotomy. Analysis was by intention to treat. Findings 96 patients were randomly assigned CWU and 92 CWU+PET. Two patients in the CWU+PET group did not undergo PET. 18 patients in the CWU group and 32 in the CWU+PET group did not have thoracotomy. In the CWU group, 39 (41%) patients had a futile thoracotomy, compared with 19 (21%) in the CWU+PET group (relative reduction 51%, 95% Cl 32–80%; p=0·003). Interpretation Addition of PET to conventional workup prevented unnecessary surgery in one out of five patients with suspected non-small-cell lung cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI